Iridex Corp
IRIXIridex Corporation (IRIX) is a medical device company specializing in ophthalmic surgical and laser therapy systems. Founded in 1984, the company develops innovative laser products for the treatment of ocular diseases, primarily focusing on minimally invasive procedures for conditions such as glaucoma, retinal therapy, and diabetic retinopathy. Iridex's products are used by ophthalmologists worldwide to improve patient outcomes through precise and effective laser treatments.
Company News
An independent study demonstrated that retreatment with MicroPulse® transscleral laser technology can safely reduce intraocular pressure in glaucoma patients, with IOP reductions ranging from 25% to 35% across different patient groups.
Medical device company Iridex reported Q2 2025 results with modest revenue growth, narrower net loss, and positive adjusted EBITDA, driven by cost control and operational discipline.
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, commented on recent stock price volatility, stating that there have been no material changes to its operating or financial condition.
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, announces plans to release its Q4 and full-year 2024 financial results and provide a business update on March 27, 2025.
The global medical lasers market is projected to grow from $5.99 billion in 2025 to $12.02 billion by 2033, driven by the increasing demand for non-invasive cosmetic procedures and advancements in medical laser technology.
